QUANTITATIVE EEG MONITORS SHOULD BE USED ONLY AS ADJUNCT
This article was originally published in The Gray Sheet
QUANTITATIVE EEG MONITORS SHOULD BE USED ONLY AS ADJUNCT to accepted methods of diagnosing mental, psychological, and other illnesses, FDA's Neurological Devices Advisory Panel concluded at a Sept. 16 meeting in Gaithersburg, Maryland. Although the panel did not vote on the issue, Panel Chairman Harold Wilkinson, PhD, MD, University of Massachusetts Medical Center, Worcester, summarized panel opposition to use of the devices in primary diagnosis in remarking that "there is great concern about any marketing that claims that any single device could give a clinical diagnosis."
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.